NCT05141474 — Vall d'Hebron Institute of Oncology neoantigen vaccine trial
Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
Registry record
| Registry ID | NCT05141474 ↗ |
|---|---|
| Lead sponsor | Vall d'Hebron Institute of Oncology |
| Collaborators | Banc de Sang i Teixits |
| Phase | Phase EARLY_PHASE1 |
| Status | Recruiting |
| Indication | Epithelial Tumors, Malignant, Malignant Solid Tumor |
| Enrollment | 10 participants (target) |
| Start date | 2021-10-28 |
| Primary completion | 2027-01-01 (est.) |
| Last registry update | 20 Nov 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT05141474), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.
Related trials
FAQ
What phase is NCT05141474?
NCT05141474 (Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors) is registered on ClinicalTrials.gov as Phase EARLY_PHASE1, sponsored by Vall d'Hebron Institute of Oncology.
Is NCT05141474 recruiting?
As of the 2026-11-20 registry update, NCT05141474 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT05141474?
The lead sponsor is Vall d'Hebron Institute of Oncology. Collaborators: Banc de Sang i Teixits.
What condition does NCT05141474 study?
The registered conditions are Epithelial Tumors, Malignant, Malignant Solid Tumor. Primary completion is listed as 2027-01-01 (estimated).
Are results available for NCT05141474?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT05141474.
Back to the full neoantigen vaccine trial tracker — 105 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.